
Loading, please wait...

Loading, please wait...

Antimicrobial resistance causes over one million deaths every year globally. Pathogens evolve rapidly and share genes horizontally. Consequently, many new antibiotics lose their efficacy shortly after introduction. This urgent situation requires innovative therapeutic strategies. DNA-templated silver nanoclusters represent a promising modular platform for tackling these infections. These nanoscale assemblies improve treatment potency while maintaining a low toxicity profile for human cells.
Nanoscale silver has long been known for its antimicrobial properties. However, high concentrations often lead to human toxicity. Researchers have now developed programmable DNA scaffolds to address this issue. These structures organize multiple monodisperse silver nanoclusters with high precision. Specifically, these assemblies use reactive oxygen species, such as singlet oxygen, to kill bacteria. Moreover, they disrupt bacterial membranes effectively. Notably, these nanoclusters also exhibit intrinsic fluorescence. Therefore, clinicians could potentially use them for both treatment and real-time bioimaging of infected tissues.
These novel assemblies show potent activity against antibiotic-resistant ESKAPE pathogens. Studies demonstrate their ability to reduce bacterial burden in primary bone cells infected with Staphylococcus aureus. Furthermore, the nanoclusters remain stable for four weeks at room temperature. This stability ensures they retain their antibacterial power over time without losing efficacy. Consequently, this technology provides a dual-function tool for next-generation medicine, combining targeted therapy with diagnostic capabilities.
Standard silver nanoparticles often require high concentrations which can be toxic to human cells. In contrast, DNA-templated silver nanoclusters use DNA scaffolds to organize silver at the atomic level. This increases antimicrobial potency and stability while providing intrinsic fluorescence for bioimaging.
Yes, they are highly effective against ESKAPE pathogens. These include common hospital-acquired bacteria like Staphylococcus aureus and Pseudomonas aeruginosa that often resist traditional antibiotics through rapid evolution and gene transfer.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Skelly E et al. Spatially Organized DNA-Templated Silver Nanoclusters as Potent Antimicrobial Agents for ESKAPE Infections. ACS Appl Mater Interfaces. 2026 Mar 16. doi: 10.1021/acsami.5c25898. PMID: 41839722.
Tacconelli E, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-327.
Mulani MS, et al. Emerging Strategies to Combat ESKAPE Pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). Front Pharmacol. 2019;10:539.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New DNA-templated silver nanoclusters target drug-resistant ESKAPE pathogens using reactive oxygen species, offering a stable and low-toxicity treatment opt...
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today